Depression News and Research

Latest Depression News and Research

Molecular imaging technique pinpoints changes that take place in injured brain

Results from a study published in the November issue of The Journal of Nuclear Medicine (JNM) show that powerful imaging techniques positron emission tomography (PET) fused with magnetic resonance imaging (MRI) are helping researchers better understand the long-term functional and structural changes that take place after traumatic brain injury (TBI).

2 Nov 2010

Physical activity outside of work reduces risk of depression: Study

Researchers have found evidence that regular exercise reduces the risk of depression provided the activity is carried out in leisure time. People who exert themselves at work, for instance by digging up roads or heavy lifting, were no less likely to suffer depression than those in sedentary desk jobs.

1 Nov 2010

New PHQ-9 screening test evaluates major depression in adults

Primary-care clinicians know teen depression is common, but they've lacked a reliable screening test for it. Now researchers at the University of Washington (UW), Seattle Children's, and Group Health report the PHQ-9 is a good screening test for major depression in adolescents.

1 Nov 2010

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.

1 Nov 2010

New Specialist Library offers treatment for eating disorders

Eating Disorder Hope, a respected independent resource for individuals suffering from anorexia, bulimia, binge eating and other body image and eating disorders, has expanded its Eating Disorder Specialist Library to further help sufferers of anorexia, bulimia and binge eating disorder find treatment options.

30 Oct 2010

CONCERTA improves handwriting performance in children with ADHD: Study

Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.

30 Oct 2010

Bed rest may harm mother and baby in pregnancy complications

Bed rest may not be the best option for preventing preterm labor and may even cause harm to the mother and baby, according to an integrative literature review in a special issue on "Women's Health Across the Lifespan" in Biological Research for Nursing (published by SAGE).

30 Oct 2010

New Chicago Sports Concussion Clinic at Rush University provides proper diagnosis for athletes

Concussions, like any injury, need proper assessment and time to heal. Some may brush off an injury to the head, but an injury to the brain may be severe with possible long-term consequences. Athletes or individuals who suffer a bump or blow to the head now can see a physician for assessment within 24 to 48 hours at the new Chicago Sports Concussion Clinic at Rush University Medical Center.

29 Oct 2010

EUCOMMTOOLS partners to receive 12 million euros research funding from European Commission

The findings will contribute to a better understanding of the pathogenesis of widespread diseases such as Alzheimer's, depression, diabetes, chronic lung diseases or cancer. Over the next five years, the eight EUCOMMTOOLS partners, coordinated by Professor Wolfgang Wurst of Helmholtz Zentrum M-nchen, will receive research funding amounting to approximately 12 million euros from the European Commission.

29 Oct 2010

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Shire plc the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in patients who have had residual symptoms of depression following treatment with LEXAPRO(escitlopram) for Major Depressive Disorder (MDD).

29 Oct 2010

New e-SMART-HD program helps improve doctor-patient communications

While many young adults will share the details of their daily lives with friends on Facebook, communicating with their doctors about mental illness is another story. E-SMART-MH, developed at Case Western Reserve University, might improve those communications.

29 Oct 2010

New eight-month pilot program to advance standards of care for people with schizophrenia

The National Council for Community Behavioral Healthcare (National Council) today announced a new eight-month pilot program designed to advance standards of care for people living with schizophrenia. This initiative at 10 community behavioral health organizations nationwide is designed to improve the daily functioning of people with schizophrenia and raise expectations for what is achievable.

29 Oct 2010

Mary Ann Liebert launches Brain Connectivity journal

Mary Ann Liebert, Inc. announces the release of a new peer-reviewed journal in an expanding area of systems neuroscience, Brain Connectivity. This timely new journal is positioned to become the premier source of cutting-edge basic and clinical neuroscience research aimed at better understanding of structural and functional connections in the brain and how these connections are altered by neurological disorders.

29 Oct 2010

Low household income associated with chronic migraine

New data presented today at The 2010 European Headache and Migraine Trust International Congress (EHMTIC) shows that persons with chronic migraine (headache on greater than or equal to 15 days per month) are much more likely to have annual household incomes below $30,000 than those with episodic migraine (headache on < 15 days per month).

29 Oct 2010

Outcome-based contract between CIGNA and Merck helps diabetics control blood sugar levels

The first national outcome-based contract between a pharmaceutical company and a pharmacy benefit management company resulted in an increase in the number of people with type 2 diabetes who were able to control their blood sugar levels by taking their medications appropriately.

29 Oct 2010

Long hours and nights on call lead to surgeon distress

Just as with everyone else perhaps, the more hours surgeons work, and the more nights they spend on call each week, the more likely they are to face burn-out, depression, dissatisfaction with their careers and serious work-home conflicts, according to a major new study led by Johns Hopkins and Mayo Clinic researchers.

29 Oct 2010

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended September 30, 2010.

29 Oct 2010

World's largest research initiative to mutate all mouse genes

The world's largest research initiative to mutate all mouse genes is now able to reach the summit because the ambitious EUCOMMTOOLS project started on October 1, 2010. This project is being coordinated by Helmholtz Zentrum München and will finalize the groundwork for the analysis of all mouse gene functions. The findings will contribute to a better understanding of the pathogenesis of widespread diseases such as Alzheimer's, depression, diabetes, chronic lung diseases or cancer.

28 Oct 2010

Evotec grants Jingxin Pharma rights to develop, market EVT 201 insomnia drug candidate in China

Evotec AG today announced that it has entered into a license and collaboration agreement with Zhejiang Jingxin Pharmaceutical Co., Ltd for EVT 201, a novel potential treatment for insomnia. The agreement grants Jingxin Pharma exclusive rights to develop and market the drug candidate in China. In return, Evotec will receive a small upfront payment, together with commercial milestones and significant royalties.

28 Oct 2010

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).

27 Oct 2010

Depression News and Research

Latest Depression News and Research

Molecular imaging technique pinpoints changes that take place in injured brain

Physical activity outside of work reduces risk of depression: Study

New PHQ-9 screening test evaluates major depression in adults

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

New Specialist Library offers treatment for eating disorders

CONCERTA improves handwriting performance in children with ADHD: Study

Bed rest may harm mother and baby in pregnancy complications

New Chicago Sports Concussion Clinic at Rush University provides proper diagnosis for athletes

EUCOMMTOOLS partners to receive 12 million euros research funding from European Commission

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

New e-SMART-HD program helps improve doctor-patient communications

New eight-month pilot program to advance standards of care for people with schizophrenia

Mary Ann Liebert launches Brain Connectivity journal

Low household income associated with chronic migraine

Outcome-based contract between CIGNA and Merck helps diabetics control blood sugar levels

Long hours and nights on call lead to surgeon distress

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

World's largest research initiative to mutate all mouse genes

Evotec grants Jingxin Pharma rights to develop, market EVT 201 insomnia drug candidate in China

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Depression News and Research

Latest Depression News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in